Sugi Predict

Sugi Predict / Compounds / SCHEMBL103112

SCHEMBL103112

SCHEMBL103112

NC(=NO)c1ccc(F)cc1

nearest known ligand 0.52

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ KDM1A O60341 4/20 0.50
▸ ALOX5 P09917 1/20 0.48
▸ RAB9A P51151 4/20 0.47
▸ NPC1 O15118 3/20 0.47
▸ PKM P14618 1/20 0.47
▸ SMN1; SMN2 Q16637 1/20 0.46
▸ GAA P10253 2/20 0.46
▸ SLC22A2 O15244 1/20 0.44
▸ SLC22A1 O15245 1/20 0.44
▸ SLC22A3 O75751 1/20 0.44
▸ PLAU P00749 1/20 0.44
▸ CES2 O00748 1/20 0.44
▸ CES1 P23141 1/20 0.44
▸ GRIN2B Q13224 1/20 0.43
▸ LMNA P02545 2/20 0.43
▸ NOS3 P29474 2/20 0.43
▸ NOS1 P29475 2/20 0.43
▸ GFER P55789 1/20 0.43
▸ KMT2A Q03164 1/20 0.43
▸ L3MBTL1 Q9Y468 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL283942 1.00 KDM1A (0.50) KDM1AALOX5RAB9ANPC1PKM
SCHEMBL103111 1.00 KDM1A (0.50) KDM1AALOX5RAB9ANPC1PKM
SCHEMBL14153243 0.93 ALOX5 (0.51) KDM1AALOX5RAB9ANPC1PKM
SCHEMBL15913193 0.88 FLT3 (0.43) KDM1AALOX5RAB9ANPC1PKM
SCHEMBL14060096 0.88 FLT3 (0.43) KDM1AALOX5RAB9ANPC1PKM
SCHEMBL21215222 0.87 KDM1A (0.60) KDM1ARAB9ANPC1GAALMNA
SCHEMBL23153560 0.80 SLC22A2 (0.50) RAB9ANPC1PKMSMN1; SMN2SLC22A2
SCHEMBL26101836 0.80 SLC22A2 (0.50) RAB9ANPC1PKMSMN1; SMN2SLC22A2
SCHEMBL10092621 0.79 KDM1A (0.54) KDM1AALOX5RAB9ANPC1GAA
SCHEMBL14384554 0.78 SMN1; SMN2 (0.49) RAB9ANPC1PKMSMN1; SMN2SLC22A2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 282 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12624011-B2 Oxadiazole derivative Sumitomo Pharma Co., Ltd. (JP) 2026-05-12 — — US disclosed
US-20260048047-A1 SMALL-MOLECULE ACTIVATORS OF MYCOBACTERIUM TUBERCULOSIS ADENYLYL CYCLASE SCRIPPS RESEARCH INST (US) 2026-02-19 — — US disclosed
EP-4624465-A1 COMPOUND SERVING AS DDR1 KINASE INHIBITOR, AND MEDICINE Nippon Shinyaku Co., Ltd. (JP) 2025-10-01 — — EP disclosed
EP-4122923-B1 OXADIAZOLE DERIVATIVE SUMITOMO PHARMA CO LTD (JP) 2025-09-10 — — EP disclosed
US-20250228242-A1 PROTEIN AGGREGATION INHIBITING COMPOUNDS FOR PLANT DISEASE CONTROL MAX-PLANCK-Gesellschaft zur Förderung der Wissenschaften e.V. (DE) 2025-07-17 — — US disclosed
CN-119855820-A Camptothecins compound and its preparation method and use 上海齐鲁制药研究中心有限公司 2025-04-18 — — CN disclosed
US-12275723-B2 Compounds and uses thereof JANSSEN PHARMACEUTICA NV (BE) 2025-04-15 — — US disclosed
CN-113382767-B Urea compounds having substituents 第一三共株式会社 2024-12-24 — — CN disclosed
US-20240400546-A1 COMPOUNDS AND USES THEREOF JANSSEN PHARMACEUTICA NV (BE) 2024-12-05 — — US disclosed
US-20240300938-A1 COMPOUNDS AND USES THEREOF JANSSEN PHARMACEUTICA NV (BE) 2024-09-12 — — US disclosed
US-6034106-A Oxadiazole benzenesulfonamides as selective β3 Agonist for the treatment of Diabetes and Obesity MERCK & CO., INC. (US) 2000-03-07 — — US disclosed
EP-0906310-A4 OXADIAZOLE BENZENESULFONAMIDES AS SELECTIVE -g(b) 3? AGONISTS FOR THE TREATMENT OF DIABETES AND OBESITY MERCK & CO INC (US) 1999-09-01 — — EP disclosed
EP-0906310-A1 OXADIAZOLE BENZENESULFONAMIDES AS SELECTIVE $g(b) 3? AGONISTS FOR THE TREATMENT OF DIABETES AND OBESITY Merck & Co., Inc. (US) 1999-04-07 — — EP disclosed
WO-1997046556-A1 OXADIAZOLE BENZENESULFONAMIDES AS SELECTIVE β3 AGONISTS FOR THE TREATMENT OF DIABETES AND OBESITY MERCK & CO., INC. (US) 1997-12-11 — — WO disclosed
US-5554626-A TREATMENT OF PARKINSON*S DISEASE, DRUG ABUSE/DEPENDENCE; COANIE/AMPHETAMINE ADDICTION NEUROSEARCH A/S (DK) 1996-09-10 — — US disclosed
US-5444070-A TREATING A DISEASE OR DISORDER WHICH IS RESPONSIVE TO THE INHIBITION OF DOPAMINE REUPTAKE BY ADMINISTERING A TROPANE DERIVATIVE NEUROSEARCH A/S (DK) 1995-08-22 — — US disclosed
US-5374636-A Antidrug abuse, antidepressants, antiParkinson activity NEUROSEARCH A/S (DK) 1994-12-20 — — US disclosed
US-5369113-A Certain 2,3-diphenyl-2-(1,2,4-oxadiazol-5-yl)tropanes useful as dopamide reuptake inhibitors NEUROSEARCH A/S (DK) 1994-11-29 — — US disclosed
EP-0604355-A2 Akyl Substituted heterocyclic compounds NEUROSEARCH A/S (DK) 1994-06-29 — — EP disclosed
US-4016170-A TRANQUILIZERS, SLEEP INDUCERS SANDOZ, INC. (US) 1977-04-05 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20240300938-A1 COMPOUNDS AND USES THEREOF NLN, ACHE, CLN6 KDM1A 4113/4885ALOX5 224/4885RAB9A 2129/4885
US-20240400546-A1 COMPOUNDS AND USES THEREOF NLN, ACHE, CLN6 KDM1A 4113/4885ALOX5 224/4885RAB9A 2129/4885
US-12275723-B2 Compounds and uses thereof NLN, ACHE, CLN6 KDM1A 4113/4885ALOX5 224/4885RAB9A 2129/4885
US-20250228242-A1 PROTEIN AGGREGATION INHIBITING COMPOUNDS FOR PLANT DISEASE CONTROL APP, APBA1, PRNP KDM1A 3814/4885ALOX5 2738/4885RAB9A 1693/4885
US-20260048047-A1 SMALL-MOLECULE ACTIVATORS OF MYCOBACTERIUM TUBERCULOSIS ADENYLYL CYCLASE FNTB, PDE7A, TBL3 KDM1A 4764/4885ALOX5 2506/4885RAB9A 544/4885
US-12624011-B2 Oxadiazole derivative HSD3B1, CBR3, CBR1 KDM1A 692/4885ALOX5 563/4885RAB9A 2533/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.